(Q34168385)

31 July 2017

1 reference

title

Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review (English)

1 reference

31 July 2017

0 references

1 reference

Burge MR

1 reference

31 July 2017

Sood V

1 reference

31 July 2017

Sobhy TA

1 reference

31 July 2017

Rassam AG

1 reference

31 July 2017

Schade DS

1 reference

31 July 2017

publication date

1 July 1999

1 reference

Diabetes, Obesity and Metabolism

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

199-206

1 reference

31 July 2017

cites work

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Incidence and Risk Factors for Serious Hypoglycemia in Older Persons Using Insulin or Sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Rates of hypoglycemia in users of sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Individual sulfonylureas and serious hypoglycemia in older people

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Comparative tolerability profiles of oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Clinical profile of the novel sulphonylurea glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Reproducibility of glycaemic thresholds for activation of counterregulatory hormones and hypoglycaemic symptoms in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Stabilization of plasma glucose during fasting; Normal variations in two separate studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00031.X

10.1046/J.1463-1326.1999.00031.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference